David H. Noyd
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David H. Noyd has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Amanda E. Janitz
University of Oklahoma Health Campus
23 shared publications - Kevin C. Oeffinger
Department of Medicine, Duke University , Durham, NC
23 shared publications - Ashley A. Baker
Department of Pediatrics, Division of Hematology Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
21 shared publications - David C. Kendrick
Department of Medical Informatics, The University of Oklahoma School of Community Medicine, Oklahoma City, Oklahoma
21 shared publications - Nancy C. Etzold
The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
21 shared publications - William Howard Beasley
Developmental and Behavioral Pediatrics, Department of Pediatrics, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma
21 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Increased Healthcare Utilization and Differential Outcomes for Pediatric Cancer Versus Non‐Cancer Patients
Background: The Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) is a data standard that enables multicenter research. Primary objective was to describe the magnitude of healthcare utilization in pediatric cancer versus non‐cancer patients. Secondary objective was to compare 6‐month clinical outcomes related to abnormal lab tests and mortality. Methods: In this multicenter retrospective study, we included pediatric patients 0–18 years at first medication administration. Cancer patients had a malignant neoplastic disease diagnosis and received chemotherapy. Index date was the first chemotherapy date. Non‐cancer patients were assigned analogous index dates based on randomly sampled first medication to chemotherapy intervals. Outcomes were measured within 6 months of index date. Healthcare utilization included encounters, procedures, radiology, lab tests, and medications. Results: Among 2810 cancer and 11,240 non‐cancer patients, all evaluated healthcare utilization measures were significantly more common in cancer patients. The largest relative differences were observed for long inpatient stay (risk ratio [RR] 26.32, 95% confidence interval [CI] 15.00–46.17), computed tomography (RR 23.59, 95% CI 19.24–28.92), blood culture (RR 37.04, 95% CI 9.58–143.14), and intravenous medication (RR 17.69, 95% CI 8.75–35.75). Death within 6 months was higher for cancer versus non‐cancer patients (RR 38.37, 95% CI 12.91–114.04). Conclusions: Using the OMOP CDM, we found greater healthcare utilization and worse clinical outcomes among pediatric cancer patients than non‐cancer patients, with the largest relative differences observed for inpatient stay, computed tomography, blood culture, and intravenous medication. These findings provide insight into resource utilization patterns and illustrate the OMOP CDM research potential for multicenter studies.
- 29 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Open AccessIncreased Healthcare Utilization and Differential Outcomes for Pediatric Cancer Versus Non‐Cancer Patients
Background: The Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) is a data standard that enables multicenter research. Primary objective was to describe the magnitude of healthcare utilization in pediatric cancer versus non‐cancer patients. Secondary objective was to compare 6‐month clinical outcomes related to abnormal lab tests and mortality. Methods: In this multicenter retrospective study, we included pediatric patients 0–18 years at first medication administration. Cancer patients had a malignant neoplastic disease diagnosis and received chemotherapy. Index date was the first chemotherapy date. Non‐cancer patients were assigned analogous index dates based on randomly sampled first medication to chemotherapy intervals. Outcomes were measured within 6 months of index date. Healthcare utilization included encounters, procedures, radiology, lab tests, and medications. Results: Among 2810 cancer and 11,240 non‐cancer patients, all evaluated healthcare utilization measures were significantly more common in cancer patients. The largest relative differences were observed for long inpatient stay (risk ratio [RR] 26.32, 95% confidence interval [CI] 15.00–46.17), computed tomography (RR 23.59, 95% CI 19.24–28.92), blood culture (RR 37.04, 95% CI 9.58–143.14), and intravenous medication (RR 17.69, 95% CI 8.75–35.75). Death within 6 months was higher for cancer versus non‐cancer patients (RR 38.37, 95% CI 12.91–114.04). Conclusions: Using the OMOP CDM, we found greater healthcare utilization and worse clinical outcomes among pediatric cancer patients than non‐cancer patients, with the largest relative differences observed for inpatient stay, computed tomography, blood culture, and intravenous medication. These findings provide insight into resource utilization patterns and illustrate the OMOP CDM research potential for multicenter studies.
- Open Access
- 28 September 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10)
Multi‐Center Evaluation of Opioid Administration or Prescription in Pediatric Oncology Patients Using the OMOP CDM
Purpose: Opioid use in pediatric oncology is poorly characterized. The primary objective was to describe opioid administration or prescription patterns in pediatric oncology patients. Methods: In this multi‐center retrospective study conducted across three sites, we included patients aged 0–19 years with a malignant neoplastic disease who received their first chemotherapy between January 2019 and March 2024. Data were extracted from each site's Observational Medical Outcomes Partnership Common Data Model. We described patient characteristics based on: (1) first opioid administration or prescription, overall and for each specific opioid; and (2) all opioid administrations or prescriptions, overall and for each specific opioid. We also evaluated variability in opioid and naloxone use. Results: Of 2903 pediatric patients with cancer, 2707 (93.2%) were administered or prescribed at least one opioid. Among these patients, fentanyl was the most common (92.4%), followed by morphine (68.7%), hydromorphone (55.3%), and oxycodone (38.6%). Across centers, the proportion of patients receiving fentanyl ranged from 90.9% to 94.9%, morphine from 34.0% to 89.2%, oxycodone from 0.9% to 76.1%, and naloxone from 2.4% to 29.5%. Overall, 10.9% were administered or prescribed naloxone, but among 169 methadone patients, 43.5% were administered or prescribed it. Of the 153,849 total opioid administrations or prescriptions, 22.4% occurred more than 12 months after initiating chemotherapy. Conclusions: Among pediatric patients with cancer who receive chemotherapy, 93.2% were administered or prescribed at least one opioid; fentanyl was the most common. There was heterogeneity in opioid choice and naloxone use across sites. These findings lay preliminary groundwork for understanding opioid use patterns and identifying potential areas for practice improvement in pediatric oncology.
- 28 September 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10)
Open AccessMulti‐Center Evaluation of Opioid Administration or Prescription in Pediatric Oncology Patients Using the OMOP CDM
Purpose: Opioid use in pediatric oncology is poorly characterized. The primary objective was to describe opioid administration or prescription patterns in pediatric oncology patients. Methods: In this multi‐center retrospective study conducted across three sites, we included patients aged 0–19 years with a malignant neoplastic disease who received their first chemotherapy between January 2019 and March 2024. Data were extracted from each site's Observational Medical Outcomes Partnership Common Data Model. We described patient characteristics based on: (1) first opioid administration or prescription, overall and for each specific opioid; and (2) all opioid administrations or prescriptions, overall and for each specific opioid. We also evaluated variability in opioid and naloxone use. Results: Of 2903 pediatric patients with cancer, 2707 (93.2%) were administered or prescribed at least one opioid. Among these patients, fentanyl was the most common (92.4%), followed by morphine (68.7%), hydromorphone (55.3%), and oxycodone (38.6%). Across centers, the proportion of patients receiving fentanyl ranged from 90.9% to 94.9%, morphine from 34.0% to 89.2%, oxycodone from 0.9% to 76.1%, and naloxone from 2.4% to 29.5%. Overall, 10.9% were administered or prescribed naloxone, but among 169 methadone patients, 43.5% were administered or prescribed it. Of the 153,849 total opioid administrations or prescriptions, 22.4% occurred more than 12 months after initiating chemotherapy. Conclusions: Among pediatric patients with cancer who receive chemotherapy, 93.2% were administered or prescribed at least one opioid; fentanyl was the most common. There was heterogeneity in opioid choice and naloxone use across sites. These findings lay preliminary groundwork for understanding opioid use patterns and identifying potential areas for practice improvement in pediatric oncology.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (1) , e2600005
Empowering Children and Adolescents With Cancer Through Novel, Electronic Health Record–Embedded Symptom Management Tools
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (1) , e2600005
Empowering Children and Adolescents With Cancer Through Novel, Electronic Health Record–Embedded Symptom Management Tools
- Open Access
- 2 December 2025
- Published by Taylor & Francis in Cancer Survivorship Research & Care
- Vol. 3 (1)
Barriers to care for childhood cancer survivors at risk for late cardiovascular disease: a mixed methods approach
Cardiovascular disease (CVD) represents a leading cause of late morbidity and mortality among survivors of childhood cancer. This study aimed to address barriers to longitudinal survivorship-focused care. A previously validated late cardiovascular risk calculator was implemented based on data elements from Passport for Care in a survivorship cohort in Oklahoma. Survivors at moderate and high risk for late CVD were consented and invited to complete a needs assessment survey with knowledge questions on cardiotoxicity. Thematic analysis of interviews with survivors explored barriers to care. Among survivors with PFC (n=477), 71 and 246 were high and moderate risk, respectively. Of the 317 eligible survivors, 80 were contacted and signed electronic consent. Sixty-four percent of participants completed the survey (n=49; 32 survivors and 17 parents or guardians). Areas of greatest need included improved information delivery and financial concerns. Interviews of survivors (n=9) revealed themes such as distance to the hospital, transportation, financial hardship, lack of information, and transitions to adult care as significant barriers to longitudinal survivorship-focused care. Unaddressed information needs, socioeconomic factors, and geography were significant barriers for survivors. Participants were receptive to telehealth-based interventions.
- 2 December 2025
- Published by Taylor & Francis in Cancer Survivorship Research & Care
- Vol. 3 (1)
Open AccessBarriers to care for childhood cancer survivors at risk for late cardiovascular disease: a mixed methods approach
Cardiovascular disease (CVD) represents a leading cause of late morbidity and mortality among survivors of childhood cancer. This study aimed to address barriers to longitudinal survivorship-focused care. A previously validated late cardiovascular risk calculator was implemented based on data elements from Passport for Care in a survivorship cohort in Oklahoma. Survivors at moderate and high risk for late CVD were consented and invited to complete a needs assessment survey with knowledge questions on cardiotoxicity. Thematic analysis of interviews with survivors explored barriers to care. Among survivors with PFC (n=477), 71 and 246 were high and moderate risk, respectively. Of the 317 eligible survivors, 80 were contacted and signed electronic consent. Sixty-four percent of participants completed the survey (n=49; 32 survivors and 17 parents or guardians). Areas of greatest need included improved information delivery and financial concerns. Interviews of survivors (n=9) revealed themes such as distance to the hospital, transportation, financial hardship, lack of information, and transitions to adult care as significant barriers to longitudinal survivorship-focused care. Unaddressed information needs, socioeconomic factors, and geography were significant barriers for survivors. Participants were receptive to telehealth-based interventions.
- Open Access
- 1 December 2025
- Published by SAGE Publications in Journal of Adolescent and Young Adult Oncology
- Vol. 14 (6) , 516-524
Rurality, Cardiovascular Risk Factors, and Early Cardiovascular Disease Among Childhood, Adolescent, and Young Adult Cancer Survivors
Purpose: Cardiovascular risk factors (CVRFs) later in life potentiate risk for late cardiovascular disease (CVD) from cardiotoxic treatment among survivors. This study evaluated the association of baseline CVRFs and CVD in the early survivorship period. Methods: This analysis included patients ages 0–29 at initial diagnosis and reported in the institutional cancer registry between 2010 and 2017 ( n = 1228). Patients who died within 5 years ( n = 168), those not seen in the oncology clinic ( n = 312), and those with CVD within one year of diagnosis ( n = 17) were excluded. CVRFs (hypertension, diabetes, dyslipidemia, and obesity) within 1 year of initial diagnosis were constructed and extracted from the electronic health record based on discrete observations, ICD9/10 codes, and RxNorm codes for antihypertensives. Results: Among survivors ( n = 731), 10 incident cases (1.4%) of CVD were observed between 1 and 5 years after the initial diagnosis. Public health insurance ( p = 0.04) and late effects risk strata ( p = 0.01) were positively associated with CVD. Among survivors with public insurance ( n = 495), two additional cases of CVD were identified from claims data with an incidence of 2.4%. Survivors from rural areas had a 4.1 times greater risk of CVD compared with survivors from urban areas (95% CI: 1.1–15.3), despite adjustment for late effects risk strata. Conclusion: Clinically computable phenotypes for CVRFs among survivors through informatics methods were feasible. Although CVRFs were not associated with CVD in the early survivorship period, survivors from rural areas were more likely to develop CVD.
- 1 December 2025
- Published by SAGE Publications in Journal of Adolescent and Young Adult Oncology
- Vol. 14 (6) , 516-524
Open AccessRurality, Cardiovascular Risk Factors, and Early Cardiovascular Disease Among Childhood, Adolescent, and Young Adult Cancer Survivors
Purpose: Cardiovascular risk factors (CVRFs) later in life potentiate risk for late cardiovascular disease (CVD) from cardiotoxic treatment among survivors. This study evaluated the association of baseline CVRFs and CVD in the early survivorship period. Methods: This analysis included patients ages 0–29 at initial diagnosis and reported in the institutional cancer registry between 2010 and 2017 ( n = 1228). Patients who died within 5 years ( n = 168), those not seen in the oncology clinic ( n = 312), and those with CVD within one year of diagnosis ( n = 17) were excluded. CVRFs (hypertension, diabetes, dyslipidemia, and obesity) within 1 year of initial diagnosis were constructed and extracted from the electronic health record based on discrete observations, ICD9/10 codes, and RxNorm codes for antihypertensives. Results: Among survivors ( n = 731), 10 incident cases (1.4%) of CVD were observed between 1 and 5 years after the initial diagnosis. Public health insurance ( p = 0.04) and late effects risk strata ( p = 0.01) were positively associated with CVD. Among survivors with public insurance ( n = 495), two additional cases of CVD were identified from claims data with an incidence of 2.4%. Survivors from rural areas had a 4.1 times greater risk of CVD compared with survivors from urban areas (95% CI: 1.1–15.3), despite adjustment for late effects risk strata. Conclusion: Clinically computable phenotypes for CVRFs among survivors through informatics methods were feasible. Although CVRFs were not associated with CVD in the early survivorship period, survivors from rural areas were more likely to develop CVD.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Rural, Large Town, and Urban Differences in Optimal Subspecialty Follow-up and Survivorship Care Plan Documentation among Childhood Cancer Survivors
Subanalysis and geographical map for Oklahoma City Urban, non-Oklahoma City urban, large town, and small town/isolated rural areas in Oklahoma.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Rural, Large Town, and Urban Differences in Optimal Subspecialty Follow-up and Survivorship Care Plan Documentation among Childhood Cancer Survivors
Subanalysis and geographical map for Oklahoma City Urban, non-Oklahoma City urban, large town, and small town/isolated rural areas in Oklahoma.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Rural, Large Town, and Urban Differences in Optimal Subspecialty Follow-up and Survivorship Care Plan Documentation among Childhood Cancer Survivors
Rural-Urban Commuting Area (RUCA) codes, definitions, and categories (adapted from https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes/ and https://depts.washington.edu/uwruca/ruca-uses.php)
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Rural, Large Town, and Urban Differences in Optimal Subspecialty Follow-up and Survivorship Care Plan Documentation among Childhood Cancer Survivors
Rural-Urban Commuting Area (RUCA) codes, definitions, and categories (adapted from https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes/ and https://depts.washington.edu/uwruca/ruca-uses.php)
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Rural, Large Town, and Urban Differences in Optimal Subspecialty Follow-up and Survivorship Care Plan Documentation among Childhood Cancer Survivors
Directed acyclic graph of the potential associations between rurality at time of diagnosis and optimal subspecialty follow-up among childhood cancer survivors.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Rural, Large Town, and Urban Differences in Optimal Subspecialty Follow-up and Survivorship Care Plan Documentation among Childhood Cancer Survivors
Directed acyclic graph of the potential associations between rurality at time of diagnosis and optimal subspecialty follow-up among childhood cancer survivors.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Rural, Large Town, and Urban Differences in Optimal Subspecialty Follow-up and Survivorship Care Plan Documentation among Childhood Cancer Survivors
Modeling for the association between rurality, with subanalysis for non-Oklahoma City urban areas, and the risk of suboptimal subspecialty follow-up care five to seven years after initial diagnosis using Modified Poisson Regression with robust error variance. (n=449)
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Rural, Large Town, and Urban Differences in Optimal Subspecialty Follow-up and Survivorship Care Plan Documentation among Childhood Cancer Survivors
Modeling for the association between rurality, with subanalysis for non-Oklahoma City urban areas, and the risk of suboptimal subspecialty follow-up care five to seven years after initial diagnosis using Modified Poisson Regression with robust error variance. (n=449)
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Rural, Large Town, and Urban Differences in Optimal Subspecialty Follow-up and Survivorship Care Plan Documentation among Childhood Cancer Survivors
Directed acyclic graph of the potential associations between rurality at time of diagnosis and survivors with Passport for Care
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Rural, Large Town, and Urban Differences in Optimal Subspecialty Follow-up and Survivorship Care Plan Documentation among Childhood Cancer Survivors
Directed acyclic graph of the potential associations between rurality at time of diagnosis and survivors with Passport for Care